Dose Reduction of Meloxicam in Dogs with Osteoarthritis-Associated Pain and Impaired Mobility

Journal of Veterinary Internal Medicine

Volumn 25, Issue 6, 2011, Pages 1298-1305

  Wernham, B G J ^a   Trumpatori, B ^a   Hash, J ^a   Lipsett, J ^a   Davidson, G ^a   Wackerow, P ^a   Thomson, A ^a   Lascelles, B D X ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Arthritis; Chronic; Nonsteroidal anti inflammatory drug

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; OSTEOARTHRITIS; PAIN; RANDOMIZED CONTROLLED TRIAL; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; OSTEOARTHRITIS; PAIN; THIAZINES; THIAZOLES; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 81355141951     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00825.x     Document Type: Article

References (27)

1. Johnston JA, Austin C, Breur GJ. Incidence of canine appendicular musculoskeletal disorders in 16 veterinary teaching hospitals from 1980 through 1989. Vet Comp Orthop Traumatol 1994;7:56-69.
2. Innes JF, Clayton J, Lascelles BD. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec 2010;166:226-230.
3. Lascelles BD, Blikslager AT, Fox SM, et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 2005;227:1112-1117.
4. Lascelles BD, McFarland JM, Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Vet Ther 2005;6:237-251.
5. Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. Vet Clin North Am Small Anim Pract 2008;38:1243-1266.
6. Doig PA, Purbrick KA, Hare JE, et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000;41:296-300.
7. Luna SP, Basilio AC, Steagall PV, et al. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 2007;68:258-264.
8. Moreau M, Dupuis J, Bonneau NH, et al. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec 2003;152:323-329.
9. Nell T, Bergman J, Hoeijmakers M, et al. Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation. J Small Anim Pract 2002;43:208-212.
10. Hielm-Bjorkman AK, Rita H, Tulamo RM. Psychometric testing of the Helsinki chronic pain index by completion of a questionnaire in Finnish by owners of dogs with chronic signs of pain caused by osteoarthritis. Am J Vet Res 2009;70:727-734.
11. Hielm-Bjorkman AK, Kuusela E, Liman A, et al. Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs. J Am Vet Med Assoc 2003;222:1552-1558.
12. Brown DC, Boston RC, Coyne JC, et al. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res 2007;68:631-637.
13. Brown DC, Boston RC, Coyne JC, et al. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2008;233:1278-1283.
14. Brown DC, Michel KE, Love M, et al. Evaluation of the effect of signalment and body conformation on activity monitoring in companion dogs. Am J Vet Res 2010;71:322-325.
15. Brown DC, Boston RC, Farrar JT. Use of an activity monitor to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2010;237:66-70.
16. Dow C, Michel KE, Love M, et al. Evaluation of optimal sampling interval for activity monitoring in companion dogs. Am J Vet Res 2009;70:444-448.
17. Hansen BD, Lascelles BD, Keene BW, et al. Evaluation of an accelerometer for at-home monitoring of spontaneous activity in dogs. Am J Vet Res 2007;68:468-475.
18. Lascelles BD, Freire M, Roe SC, et al. Evaluation of functional outcome after BFX total hip replacement using a pressure sensitive walkway. Vet Surg 2010;39:71-77.
19. Lascelles BD, Roe SC, Smith E, et al. Evaluation of a pressure walkway system for measurement of vertical limb forces in clinically normal dogs. Am J Vet Res 2006;67:277-282.
20. Lascelles BD, Gaynor JS, Smith ES, et al. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Intern Med 2008;22:53-59.
21. Luyten FP, Geusens P, Malaise M, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis 2007;66:99-106.
22. Horstman CL, Conzemius MG, Evans R, et al. Assessing the efficacy of perioperative oral carprofen after cranial cruciate surgery using noninvasive, objective pressure platform gait analysis. Vet Surg 2004;33:286-292.
23. Hernandez-Molina G, Reichenbach S, Zhang B, et al. Effect of therapeutic exercise for hip osteoarthritis pain: Results of a meta-analysis. Arthritis Rheum 2008;59:1221-1228.
24. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-499.
25. Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-1266.
26. Telleria-Diaz A, Schmidt M, Kreusch S, et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 2010;148:26-35.
27. Sycha T, Anzenhofer S, Lehr S, et al. Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: A randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain 2005;113:316-322.